TrovaGene (TROV) Precision Cancer Monitoring Data Positive
Zacks Investment Research | Nov 28, 2016 08:56PM ET
San Diego, CA-based TrovaGene Inc. (NASDAQ:TROV) , a molecular diagnostic company, recently announced encouraging data pertaining to its Precision Cancer Monitoring (PCM) technology for both urine and plasma EGFR mutation testing. Notably, the results demonstrated greater detection sensitivity for PCM compared to tissue testing alone. The data will be presented in Vienna, Austria at the 17th World Conference on Lung Cancer.
Meanwhile, TrovaGene lost 4.8% to close at $2.95 following the news. The current trends also reveal lackluster sentiments as TrovaGene represents a negative one-year return of 54.3%, way lower than the S&P 500’s 5.8% over the same time frame.
Coming to the latest development, TrovaGene's abstract named, ‘A Highly Sensitive Next Generation Sequencing Platform for Detection of NSCLC EGFR T790M in Urine and Plasma’ was selected for an oral presentation at the conference. Notably, the PCM technology highlights the company’s flagship TROVERA urine and blood liquid biopsy platform in patients with late-stage non-small cell lung cancer progressing (NSCLC).
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.